Mucosal vaccines are designed to target the mucous membranes of the body, such as those in the nose, mouth, lungs, and gastrointestinal tract, where many pathogens first enter the body. These vaccines stimulate the immune system at the site of infection, providing protection before the pathogen can spread to other parts of the body. Mucosal immunity is crucial for combating diseases like influenza, rotavirus, and COVID-19, where the primary route of infection is through the mucosal surfaces. Delivery strategies for mucosal vaccines have evolved to ensure they effectively target these sites. Nasal sprays, oral vaccines, and aerosolized formulations are some of the methods being explored to administer mucosal vaccines. These delivery systems need to overcome challenges such as ensuring stability and effectively targeting the right cells in the mucosal tissues. Advancing mucosal vaccine technology has the potential to provide more effective and user-friendly vaccines, especially for respiratory and gastrointestinal infections.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States